These metabolic changes may underlie pathologic immune activation in ANCA associated vasculitis, as well as potentially contributing to the differing clinical phenotype between PR3- and MPO-ANCA positive patients. The gene discussed is PRTN3; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.